查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2096646

非類固醇消炎劑市場－2026-2032年全球市場預測

Non-steroidal Anti-inflammatory Drugs Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，非類固醇消炎劑(NSAID) 市場將成長至 388.1 億美元，複合年成長率為 6.71%。

主要市場統計數據
基準年 2025 246.2億美元
預計年份：2026年 262.2億美元
預測年份：2032年 388.1億美元
複合年成長率 (%) 6.71%

非類固醇消炎劑（NSAIDs），包括處方藥和非處方藥，仍是治療疼痛、發炎和發燒最廣泛使用的藥物之一。這類藥物包括非選擇性類風濕性關節炎抑制劑和COX-2選擇性抑制劑，用於治療骨關節炎、類風濕性關節炎、月經疼痛、Cyclooxygenase、頭痛、牙痛、術後疼痛和急性發炎性疾病等。人口老化、慢性疼痛盛行率上升、自我治療增加以及臨床上持續依賴NSAIDs作為鎮痛藥以減少鴉片類藥物的使用，都影響著NSAIDs的需求。

此外，目前非類固醇抗發炎藥物（NSAIDs）的安全性問題已得到充分證實，尤其是在老年患者和合併多種疾病的患者中，包括消化道出血、腎功能損害、心血管風險、高血壓、超敏反應和藥物交互作用。監管機構和臨床指引始終強調風險分層、最小有效劑量、適當的最短給藥療程、高風險患者的胃黏膜保護，以及根據個體的心血管、胃腸道、腎臟、肝臟和懷孕相關情況謹慎選擇藥物。隨著醫療保健系統尋求更安全的疼痛管理途徑，NSAIDs 的策略越來越注重製劑創新、真實世界數據、藥物安全監測、數位化決策支援和加強病患教育。

非類固醇抗發炎藥領域的變革性變化

隨著醫療服務提供者在提高藥物可及性和安全性期望之間尋求平衡，非類固醇抗發炎藥（NSAIDs）市場正在經歷結構性變革。其中一個顯著轉變是，疼痛管理正從一般性疼痛管理轉變為個人化鎮痛藥物。這種方法要求臨床醫師在推薦NSAIDs之前，評估患者的消化器官系統風險、心血管病史、腎功能、年齡、合併使用的抗凝血劑、抗血小板藥物、糖皮質激素、選擇性血清素再回收抑制劑（SSRIs）、降血壓藥物以及懷孕狀況。這種方法體現了實證藥物配方和藥物安全規範在基層醫療、風濕病學、整形外科、牙科、運動醫學和手術全期護理等領域的更緊密結合。

人工智慧對非類固醇抗發炎藥的累積影響

人工智慧正透過藥物安全分析、臨床決策支援、病人參與和研究，對非類固醇抗發炎藥（NSAIDs）價值鏈產生日益顯著的影響。在藥物安全監測領域，人工智慧驅動的自然語言處理和訊號檢測技術能夠分析不利事件報告、電子健康記錄、保險理賠數據、科學文獻和消費者安全說明，從而識別與消化道出血、腎功能損害、心血管事件、超敏反應、藥物濫用和藥物交互作用相關的模式。這些功能支援快速篩選安全訊號和進行更有針對性的風險管理活動，同時也需要人工監督、檢驗的資料集和透明的管治。

亞太地區、北美地區、拉丁美洲地區、歐洲地區以及中東和非洲地區的關鍵區域洞察

在亞太地區，中國、印度、日本、韓國和澳洲等國家大規模的患者群體、高發生率的肌肉骨骼疾病、快速的都市化進程、藥房的普及以及醫療保健利用率的提高，推動了非類固醇抗發炎藥（NSAIDs）的使用。該地區既擁有成熟的法規環境，也具備快速發展的醫療保健體系，因此在製劑管理、市場供應和患者自我用藥方面呈現出多樣化的模式。在北美，對NSAIDs的需求受到慢性疼痛管理、運動傷害、關節炎負擔、限制鴉片類藥物使用的臨床方案以及對藥物安全監測的高期望等因素的影響。在美國和加拿大，附加檔、心血管和消化器官系統警告、藥物治療管理以及實證製劑的研發都備受重視。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

在東協，由於都市區醫療保健服務覆蓋範圍擴大、中產階級壯大、消費者與零售藥店的互動增多以及對肌肉骨骼和炎症性疾病的認知提高，非類固醇抗發炎藥（NSAIDs）的使用量正在增加。由於監管執法力度和自我用藥習慣各不相同，藥劑師諮詢和公眾意識宣傳活動在全部區域尤其重要。在海灣合作理事會（GCC）國家，儘管標準化的醫療保健服務、電子處方箋系統、醫保覆蓋範圍和醫院疼痛管理方案發展勢頭強勁，但代謝、腎臟和心血管風險因素的高發生率凸顯了NSAIDs風險評估的重要性。

來自主要非類固醇抗發炎藥市場各國的關鍵見解

在美國，非處方非類固醇抗發炎藥（OTC NSAIDs）的廣泛普及、對無鴉片類藥物鎮痛的重視以及對心血管、消化器官系統、腎臟和妊娠相關問題的警告給予高度關注是其特點。在加拿大，藥劑師的參與、實證自我護理以及老年人和慢性疾病患者謹慎使用非類固醇抗發炎藥物備受重視。在墨西哥，零售藥局的參與度很高，由於對價格合理的鎮痛藥需求旺盛，合理用藥和消費者教育對於確保安全用藥至關重要。在巴西，這些因素共同導致了對疼痛和發炎治療藥物的高需求，同時，監管機構也日益關注藥品品質、藥房操作規範和藥物安全監測。

非類固醇抗發炎藥產業領導者使用的實用建議

產業領導者應優先考慮以安全性為中心的產品差異化，透過更清晰的標籤、病患教育、藥劑師培訓以及對風險篩檢工具的投資，來支持非類固醇抗發炎藥（NSAIDs）的合理使用。產品策略應與臨床對局部用藥製劑的需求、旨在保護胃黏膜的聯合治療方案、在適當情況下應用緩釋技術以及在保持安全標準的同時提高用藥便利性的製劑相一致。此外，各機構應透過整合真實世界數據、不利事件監測以及處方藥和非處方藥（OTC）管道的預防性安全訊號評估，來加強其藥物安全監測系統。

調查方法

本執行摘要採用系統性的二手研究方法編寫，基於公開可查且檢驗的資訊來源，包括監管指南、臨床實踐指南、藥物安全檢驗資訊、同行評審的醫學文獻、公共衛生出版物和藥物安全資源。該調查方法強調跨多個證據類別進行三角研究途徑，以確保說明反映的是已建立的臨床和監管知識，而非推測性的市場假設。

結論：以負責任的獲取和安全性為優先的創新正在塑造非類固醇抗發炎藥物的未來。

非類固醇消炎劑）在全球疼痛和發炎管理中繼續發揮核心作用，這得益於其廣泛的臨床效用、在非處方藥市場的充足供應以及在遏制鴉片類藥物濫用的治療策略中日益重要的地位。同時，由於其已知的胃腸道、腎臟、心血管、懷孕相關以及藥物交互作用等風險，此類藥物需要嚴格的安全管理。目前認為，最具競爭力和臨床責任感的策略是將藥物可近性、風險導向的用藥指南、製劑創新、藥物安全監測以及透明的患者資訊相結合。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章非類固醇消炎劑市場：依藥物類別分類

  • 乙酸衍生物
    • 雙氯芬酸鈉
    • Ketorolac
  • Phenamate系列
    • 氟苯那敏酸
    • 甲芬那酸
  • Oxycam系統
    • Piroxicam
    • 替諾昔康
  • 丙酸衍生物
    • 氟比洛芬
    • Ibuprofen
    • 酮洛芬
    • 萘普生
  • 基於水楊酸鹽的藥物
    • 阿斯匹靈
    • 二氟尼柳
  • 選擇性COX-2抑制劑（昔布類）
    • 塞來昔布
    • 依曲昔布

第8章非類固醇消炎劑市場：依劑型分類

  • 膠囊
  • 乳霜/凝膠
  • 粉末
  • 藥片

第9章非類固醇消炎劑市場：依給藥途徑分類

  • 口服
  • 腸外
  • 外用

第10章：非類固醇消炎劑市場：依劑型分類

  • 非處方藥
  • 僅限處方藥

第11章非類固醇消炎劑市場：依劑型分類

  • 即時發布
  • 修改版
    • 控釋
    • 延遲釋放/腸溶包衣
    • 緩釋

第12章非類固醇消炎劑市場：依病患小組

  • 成人
  • 老年人
  • 兒童

第13章非類固醇消炎劑市場：依適應症分類

  • 急性疼痛
    • 牙痛
    • 肌肉骨骼損傷（扭傷/肌肉拉傷）
    • 術後疼痛
  • 僵直性脊椎炎
  • 月經疼痛
  • 發燒/高燒
  • 偏頭痛和頭痛
  • 眼科領域的疼痛和炎症
  • 骨關節炎
  • 類風濕性關節炎

第14章非類固醇消炎劑市場：依最終用戶分類

  • 門診手術中心
  • 居家醫療
  • 醫院
  • 專科診所

第15章非類固醇消炎劑市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第16章非類固醇消炎劑市場：依病患小組

  • 成人
  • 老年人
  • 兒童

第17章非類固醇消炎劑市場：依地區分類

  • 歐洲
  • 北美洲
  • 亞太地區
  • 拉丁美洲
  • 非洲
  • 中東

第18章非類固醇消炎劑市場：依組別分類

  • NATO
  • G7
  • EU
  • BRICS
  • ASEAN
  • GCC

第19章非類固醇消炎劑市場：依國家分類

  • 美國
  • 中國
  • 德國
  • 加拿大
  • 日本
  • 英國
  • 巴西
  • 印度
  • 墨西哥
  • 法國
  • 義大利
  • 俄羅斯
  • 澳洲
  • 韓國
  • 西班牙

第20章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第21章 公司簡介

  • Abbvie, Inc
  • Algen Healthcare Ltd.
  • Allegiant Health
  • Amgen Inc.
  • Amneal Pharmaceuticals LLC
  • Arcutis BIoTherapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • BASF SE
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Clearsynth Labs Limited
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • EMS SA
  • Genentech, Inc.（F. Hoffmann-La Roche AG）
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Pharbest Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Sanofi SA
  • Spectrum Chemical Mfg. Corp.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Teikoku Seiyaku Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Verona Pharma plc
  • Viatris Inc.
Product Code: MRR-7C50F2739687

The Non-steroidal Anti-inflammatory Drugs Market is projected to grow by USD 38.81 billion at a CAGR of 6.71% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 24.62 billion
Estimated Year [2026] USD 26.22 billion
Forecast Year [2032] USD 38.81 billion
CAGR (%) 6.71%

Non-steroidal anti-inflammatory drugs (NSAIDs) remain among the most widely used therapeutic options for pain, inflammation, and fever management across prescription and over-the-counter healthcare settings. The category includes nonselective cyclooxygenase inhibitors and COX-2 selective agents used in conditions such as osteoarthritis, rheumatoid arthritis, musculoskeletal pain, dysmenorrhea, headache, dental pain, postoperative pain, and acute inflammatory disorders. Demand is shaped by aging populations, rising chronic pain prevalence, expanding self-medication behavior, and continued clinical reliance on NSAIDs as opioid-sparing analgesics.

The NSAID landscape is also defined by well-documented safety considerations, including gastrointestinal bleeding, renal impairment, cardiovascular risk, blood pressure elevation, hypersensitivity reactions, and drug-drug interactions, particularly in older adults and patients with comorbidities. Regulatory agencies and clinical guidelines consistently emphasize risk stratification, lowest effective dose, shortest appropriate duration, gastroprotection for high-risk patients, and careful selection based on individual cardiovascular, gastrointestinal, renal, hepatic, and pregnancy-related profiles. As healthcare systems pursue safer pain management pathways, NSAID strategies are increasingly focused on formulation innovation, real-world evidence, pharmacovigilance, digital decision support, and improved patient education.

Transformative Shifts in the NSAID Landscape

The NSAID sector is undergoing structural change as healthcare providers balance broad accessibility with heightened safety expectations. A major shift is the continued movement from generalized pain treatment toward personalized analgesic selection, where clinicians evaluate gastrointestinal risk, cardiovascular history, kidney function, age, concomitant anticoagulants, antiplatelets, corticosteroids, selective serotonin reuptake inhibitors, antihypertensive therapies, and pregnancy status before recommending an NSAID. This approach reflects stronger integration of evidence-based prescribing and medication safety protocols in primary care, rheumatology, orthopedics, dentistry, sports medicine, and perioperative care.

Another transformative shift is the rising preference for topical NSAID formulations in localized musculoskeletal conditions, particularly among older adults and patients at elevated systemic adverse-event risk. Clinical guidance in several jurisdictions supports topical options for specific osteoarthritis and soft-tissue pain applications due to lower systemic exposure compared with oral formulations. At the same time, opioid stewardship programs have strengthened the role of NSAIDs in multimodal pain management, especially when combined with acetaminophen, physical therapy, local interventions, or nonpharmacological approaches. Regulatory scrutiny of labeling, contraindications, pediatric use, pregnancy warnings, cardiovascular risk communication, and over-the-counter dosing instructions continues to influence product positioning and patient counseling. Supply chain resilience, active pharmaceutical ingredient quality, and pharmacovigilance systems are also becoming critical competitive differentiators.

Cumulative Impact of Artificial Intelligence on NSAIDs

Artificial intelligence is increasingly influencing the NSAID value chain through drug safety analytics, clinical decision support, patient engagement, and research acceleration. In pharmacovigilance, AI-enabled natural language processing and signal detection can help analyze adverse-event reports, electronic health records, claims data, scientific literature, and consumer safety narratives to identify patterns related to gastrointestinal bleeding, renal injury, cardiovascular events, hypersensitivity reactions, medication overuse, and drug-drug interactions. These capabilities support faster triage of safety signals and more targeted risk-management activities while requiring human oversight, validated datasets, and transparent governance.

In clinical practice, AI-based decision support can assist prescribers and pharmacists by flagging patients at elevated NSAID risk, identifying contraindicated combinations, recommending renal function monitoring, or prompting gastroprotective strategies where clinically appropriate. AI can also support patient-facing tools that improve adherence to dosing instructions and reduce inappropriate long-duration use of over-the-counter NSAIDs. In research and development, machine learning is being used to screen anti-inflammatory mechanisms, model COX selectivity, assess toxicity signals earlier, optimize formulation characteristics, and support real-world evidence studies. However, AI adoption must address data bias, privacy regulations, explainability, cybersecurity, and clinical validation to ensure that algorithmic recommendations improve outcomes without increasing medication-related harm.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, the Middle East, and Africa

In Asia-Pacific, NSAID use is supported by large patient populations, high incidence of musculoskeletal disorders, rapid urbanization, expanding pharmacy access, and growing healthcare utilization in countries such as China, India, Japan, South Korea, and Australia. The region combines mature regulatory environments with rapidly developing healthcare systems, creating varied patterns of prescription control, over-the-counter availability, and patient self-medication. In North America, NSAID demand is shaped by chronic pain management, sports injuries, arthritis burden, opioid-sparing clinical protocols, and strong pharmacovigilance expectations. The United States and Canada place considerable emphasis on labeling, cardiovascular and gastrointestinal warnings, medication therapy management, and evidence-based prescribing.

Latin America presents a diverse environment where Brazil and Mexico are key drivers of retail pharmacy access and self-care behavior, while public health systems continue to address affordability, quality assurance, and rational medicine use. Europe is characterized by mature regulatory oversight, strong primary care systems, pharmacovigilance infrastructure, and active clinical guidance on NSAID risk mitigation, particularly for older adults and patients with cardiovascular, gastrointestinal, or renal vulnerabilities. The Middle East shows increasing use of NSAIDs through expanding hospital networks, private healthcare investment, insurance coverage, and rising chronic disease diagnosis, with Gulf countries placing greater emphasis on regulated pharmacy distribution and digital health infrastructure. Across Africa, access patterns vary widely, with NSAID use influenced by affordability, essential medicines policies, informal medicine channels, urban-rural healthcare gaps, and the need for stronger patient education on safe dosing, contraindications, and avoidance of harmful medicine combinations.

Key Group Insights Across ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN countries are experiencing rising NSAID utilization due to expanding urban healthcare access, a growing middle class, high retail pharmacy engagement, and increased recognition of musculoskeletal and inflammatory conditions. Variability in regulatory enforcement and self-medication practices makes pharmacist counseling and public education especially important across the group. The GCC shows strong momentum in regulated healthcare delivery, e-prescription systems, insurance-backed access, and hospital-based pain management protocols, while the high prevalence of metabolic, renal, and cardiovascular risk factors increases the importance of NSAID risk assessment.

Within the European Union, harmonized regulatory frameworks, robust pharmacovigilance, and coordinated medicine safety communications shape NSAID prescribing and labeling practices. EU healthcare systems place growing emphasis on appropriate use in elderly populations, renal monitoring, gastrointestinal protection, and minimization of preventable adverse drug events. BRICS countries combine large treatment populations with expanding domestic pharmaceutical capacity, increasing attention to quality standards, local manufacturing, and access to affordable pain therapies. G7 markets are defined by advanced clinical governance, strong evidence generation, digital health adoption, and mature OTC frameworks, making safety communication and real-world outcomes central priorities. NATO member countries overlap substantially with developed healthcare systems in North America and Europe, where NSAID use is influenced by military readiness, injury management, rehabilitation needs, perioperative care, and standardized clinical pathways for acute and chronic pain.

Key Country Insights Across Major NSAID Markets

The United States is shaped by extensive OTC NSAID availability, opioid-sparing pain management, and strong attention to cardiovascular, gastrointestinal, renal, and pregnancy-related warnings. Canada emphasizes pharmacist involvement, evidence-based self-care, and careful NSAID use among older adults and patients with chronic disease. Mexico demonstrates significant retail pharmacy engagement and demand for affordable analgesics, making rational use and consumer education central to safe access. Brazil combines high demand for pain and inflammation treatment with an evolving regulatory focus on medicine quality, pharmacy practices, and pharmacovigilance.

The United Kingdom, Germany, France, Italy, and Spain operate within mature European healthcare systems where clinical guidelines, prescription controls, and pharmacovigilance systems support risk-based NSAID use. Germany and France have strong physician-led prescribing cultures and established reimbursement frameworks, while the United Kingdom emphasizes primary care guidance and national medicine safety communications. Italy and Spain show substantial use in musculoskeletal pain and rheumatologic conditions, with increasing attention to older adult safety, gastroprotection, and renal risk. Russia maintains notable demand for analgesics and anti-inflammatory therapies, with access shaped by domestic pharmaceutical capacity, pharmacy distribution, and regulatory oversight.

China has broad NSAID utilization driven by a large patient base, expanding healthcare coverage, and growing treatment of arthritis and acute pain conditions. India reflects strong demand for affordable pain relief, but safe use depends heavily on physician guidance, pharmacist intervention, and control of inappropriate self-medication. Japan's aging population and high standards for medicine safety support careful NSAID selection, including attention to gastrointestinal protection and renal function. Australia has a well-established OTC and prescription environment, with public health guidance stressing safe dosing, contraindication awareness, and avoidance of use in high-risk patients without professional advice. South Korea combines advanced healthcare infrastructure, high digital adoption, and strong clinical management of chronic pain and inflammatory disorders, supporting continued refinement of NSAID stewardship.

Actionable Recommendations for NSAID Industry Leaders

Industry leaders should prioritize safety-led differentiation by investing in clearer labeling, patient education, pharmacist training, and risk-screening tools that support appropriate NSAID use. Product strategies should align with clinical demand for topical formulations, gastroprotective co-therapy considerations, controlled-release technologies where appropriate, and formulations that improve convenience while maintaining safety standards. Organizations should also strengthen pharmacovigilance systems by integrating real-world evidence, adverse-event monitoring, and proactive safety signal assessment across prescription and OTC channels.

Commercial and medical teams should collaborate with healthcare professionals to support evidence-based NSAID stewardship, especially for high-risk populations such as older adults, patients with cardiovascular disease, chronic kidney disease, peptic ulcer history, hypertension, pregnancy considerations, and those using anticoagulants or antiplatelet agents. Digital tools should be developed responsibly to guide dose selection, duration reminders, contraindication checks, renal monitoring prompts, and patient counseling. Supply chain strategies should emphasize active ingredient quality, regulatory compliance, manufacturing redundancy, and transparent sourcing. In emerging markets, leaders should focus on affordability, counterfeit prevention, rational medicine use, and pharmacy-based education to improve access without compromising safety.

Research Methodology

This executive summary is developed using a structured secondary research approach grounded in publicly available and verifiable sources, including regulatory guidance, clinical practice recommendations, pharmacovigilance communications, peer-reviewed medical literature, public health publications, and medicine safety resources. The methodology emphasizes triangulation across multiple evidence categories to ensure that statements reflect established clinical and regulatory knowledge rather than speculative market assumptions.

Research inputs are assessed for relevance to NSAID pharmacology, therapeutic use, safety risks, regional access patterns, regulatory controls, OTC availability, prescribing behavior, and emerging digital health applications. Regional, group, and country insights are synthesized qualitatively to identify adoption drivers, safety priorities, and healthcare system dynamics. The analysis avoids market sizing, share estimation, and forecasting, focusing instead on data-backed industry context, clinical relevance, regulatory direction, and actionable strategic implications for stakeholders across the NSAID ecosystem.

Conclusion: Responsible Access and Safety-Led Innovation Define the Future of NSAIDs

Non-steroidal anti-inflammatory drugs continue to play a central role in global pain and inflammation management, supported by broad clinical utility, extensive OTC access, and increasing relevance in opioid-sparing treatment strategies. At the same time, the category requires disciplined safety management due to well-established gastrointestinal, renal, cardiovascular, pregnancy-related, and interaction risks. The most competitive and clinically responsible approaches will be those that combine accessibility with risk-based guidance, formulation innovation, pharmacovigilance, and transparent patient communication.

Regional and country-level differences in healthcare infrastructure, regulatory enforcement, pharmacy practice, and self-medication behavior will continue to shape NSAID utilization. Artificial intelligence, real-world evidence, and digital decision support can enhance safety monitoring and personalized use when implemented with strong governance and clinical validation. Industry leaders that prioritize responsible access, evidence-based education, and safety-centered innovation will be best positioned to meet evolving healthcare expectations in the NSAID landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Non-steroidal Anti-inflammatory Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Acetic Acid Derivatives
    • 7.2.1. Diclofenac
    • 7.2.2. Ketorolac
  • 7.3. Fenamates
    • 7.3.1. Flufenamic Acid
    • 7.3.2. Mefenamic Acid
  • 7.4. Oxicams
    • 7.4.1. Piroxicam
    • 7.4.2. Tenoxicam
  • 7.5. Propionic Acid Derivatives
    • 7.5.1. Flurbiprofen
    • 7.5.2. Ibuprofen
    • 7.5.3. Ketoprofen
    • 7.5.4. Naproxen
  • 7.6. Salicylates
    • 7.6.1. Aspirin
    • 7.6.2. Diflunisal
  • 7.7. Selective COX-2 Inhibitors (Coxibs)
    • 7.7.1. Celecoxib
    • 7.7.2. Etoricoxib

8. Non-steroidal Anti-inflammatory Drugs Market, by Formulation

  • 8.1. Introduction
  • 8.2. Capsules
  • 8.3. Creams/Gels
  • 8.4. Powders
  • 8.5. Tablets

9. Non-steroidal Anti-inflammatory Drugs Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Oral
  • 9.3. Parenteral
  • 9.4. Topical

10. Non-steroidal Anti-inflammatory Drugs Market, by Prescription Status

  • 10.1. Introduction
  • 10.2. Over-The-Counter
  • 10.3. Prescription Only

11. Non-steroidal Anti-inflammatory Drugs Market, by Release Type

  • 11.1. Introduction
  • 11.2. Immediate-Release
  • 11.3. Modified-Release
    • 11.3.1. Controlled-Release
    • 11.3.2. Delayed-Release/Enteric-Coated
    • 11.3.3. Extended-Release

12. Non-steroidal Anti-inflammatory Drugs Market, by Patient Group

  • 12.1. Introduction
  • 12.2. Adults
  • 12.3. Geriatric
  • 12.4. Pediatric
  • 12.5. Introduction
  • 12.6. Adults
  • 12.7. Geriatric
  • 12.8. Pediatric

13. Non-steroidal Anti-inflammatory Drugs Market, by Indication

  • 13.1. Introduction
  • 13.2. Acute Pain
    • 13.2.1. Dental Pain
    • 13.2.2. Musculoskeletal Injury (Sprain/Strain)
    • 13.2.3. Postoperative Pain
  • 13.3. Ankylosing Spondylitis
  • 13.4. Dysmenorrhea
  • 13.5. Fever/Pyrexia
  • 13.6. Migraine & Headache
  • 13.7. Ophthalmic Pain & Inflammation
  • 13.8. Osteoarthritis
  • 13.9. Rheumatoid Arthritis

14. Non-steroidal Anti-inflammatory Drugs Market, by End User

  • 14.1. Introduction
  • 14.2. Ambulatory Surgical Centers
  • 14.3. Homecare
  • 14.4. Hospitals
  • 14.5. Specialty Clinics

15. Non-steroidal Anti-inflammatory Drugs Market, by Distribution Channel

  • 15.1. Introduction
  • 15.2. Hospital Pharmacies
  • 15.3. Online Pharmacies
  • 15.4. Retail Pharmacies

16. Non-steroidal Anti-inflammatory Drugs Market, by Patient Group

  • 16.1. Introduction
  • 16.2. Adults
  • 16.3. Geriatric
  • 16.4. Pediatric
  • 16.5. Introduction
  • 16.6. Adults
  • 16.7. Geriatric
  • 16.8. Pediatric

17. Non-steroidal Anti-inflammatory Drugs Market, by Region

  • 17.1. Europe
  • 17.2. North America
  • 17.3. Asia-Pacific
  • 17.4. Latin America
  • 17.5. Africa
  • 17.6. Middle East

18. Non-steroidal Anti-inflammatory Drugs Market, by Group

  • 18.1. NATO
  • 18.2. G7
  • 18.3. European Union
  • 18.4. BRICS
  • 18.5. ASEAN
  • 18.6. GCC

19. Non-steroidal Anti-inflammatory Drugs Market, by Country

  • 19.1. United States
  • 19.2. China
  • 19.3. Germany
  • 19.4. Canada
  • 19.5. Japan
  • 19.6. United Kingdom
  • 19.7. Brazil
  • 19.8. India
  • 19.9. Mexico
  • 19.10. France
  • 19.11. Italy
  • 19.12. Russia
  • 19.13. Australia
  • 19.14. South Korea
  • 19.15. Spain

20. Competitive Landscape

  • 20.1. Market Share Analysis, 2025
  • 20.2. FPNV Positioning Matrix, 2025
  • 20.3. Market Concentration Analysis, 2025
    • 20.3.1. Concentration Ratio (CR)
    • 20.3.2. Herfindahl Hirschman Index (HHI)
  • 20.4. Recent Developments & Impact Analysis, 2025
  • 20.5. Product Portfolio Analysis, 2025
  • 20.6. Benchmarking Analysis, 2025

21. Company Profiles

  • 21.1. Abbvie, Inc
  • 21.2. Algen Healthcare Ltd.
  • 21.3. Allegiant Health
  • 21.4. Amgen Inc.
  • 21.5. Amneal Pharmaceuticals LLC
  • 21.6. Arcutis Biotherapeutics, Inc.
  • 21.7. Astellas Pharma Inc.
  • 21.8. AstraZeneca PLC
  • 21.9. BASF SE
  • 21.10. Bayer AG
  • 21.11. Boehringer Ingelheim GmbH
  • 21.12. Bristol-Myers Squibb Company
  • 21.13. Clearsynth Labs Limited
  • 21.14. Daiichi Sankyo Company, Limited
  • 21.15. Dr. Reddy's Laboratories Ltd.
  • 21.16. Eisai Co., Ltd.
  • 21.17. Eli Lilly and Company
  • 21.18. EMS S.A.
  • 21.19. Genentech, Inc. by F. Hoffmann-La Roche AG
  • 21.20. Gilead Sciences, Inc.
  • 21.21. GlaxoSmithKline PLC
  • 21.22. Hikma Pharmaceuticals PLC
  • 21.23. Incyte Corporation
  • 21.24. Johnson & Johnson Services, Inc.
  • 21.25. Merck KGaA
  • 21.26. Novartis AG
  • 21.27. Pfizer Inc.
  • 21.28. Pharbest Pharmaceuticals, Inc.
  • 21.29. Sandoz International GmbH
  • 21.30. Sanofi S.A.
  • 21.31. Spectrum Chemical Mfg. Corp.
  • 21.32. Sun Pharmaceutical Industries Ltd.
  • 21.33. Takeda Pharmaceutical Co. Ltd.
  • 21.34. Teikoku Seiyaku Co., Ltd.
  • 21.35. Teva Pharmaceutical Industries Ltd.
  • 21.36. Verona Pharma plc
  • 21.37. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 31. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 33. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 34. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 35. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 36. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 37. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ACETIC ACID DERIVATIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACETIC ACID DERIVATIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ACETIC ACID DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DICLOFENAC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DICLOFENAC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DICLOFENAC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL KETOROLAC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL KETOROLAC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL KETOROLAC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FENAMATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FENAMATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FENAMATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FLUFENAMIC ACID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FLUFENAMIC ACID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FLUFENAMIC ACID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MEFENAMIC ACID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MEFENAMIC ACID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MEFENAMIC ACID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OXICAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OXICAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OXICAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PIROXICAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PIROXICAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PIROXICAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TENOXICAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TENOXICAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TENOXICAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROPIONIC ACID DERIVATIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PROPIONIC ACID DERIVATIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROPIONIC ACID DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FLURBIPROFEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FLURBIPROFEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FLURBIPROFEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IBUPROFEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IBUPROFEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IBUPROFEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL KETOPROFEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL KETOPROFEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL KETOPROFEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NAPROXEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NAPROXEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NAPROXEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SALICYLATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SALICYLATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SALICYLATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ASPIRIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ASPIRIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ASPIRIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DIFLUNISAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIFLUNISAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIFLUNISAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SELECTIVE COX-2 INHIBITORS (COXIBS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SELECTIVE COX-2 INHIBITORS (COXIBS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SELECTIVE COX-2 INHIBITORS (COXIBS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CELECOXIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELECOXIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CELECOXIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ETORICOXIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ETORICOXIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ETORICOXIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CREAMS/GELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CREAMS/GELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CREAMS/GELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POWDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL POWDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL POWDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PRESCRIPTION ONLY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PRESCRIPTION ONLY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PRESCRIPTION ONLY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMMEDIATE-RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IMMEDIATE-RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMMEDIATE-RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MODIFIED-RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MODIFIED-RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MODIFIED-RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CONTROLLED-RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CONTROLLED-RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CONTROLLED-RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DELAYED-RELEASE/ENTERIC-COATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DELAYED-RELEASE/ENTERIC-COATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DELAYED-RELEASE/ENTERIC-COATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL EXTENDED-RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL EXTENDED-RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL EXTENDED-RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ACUTE PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ACUTE PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ACUTE PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL DENTAL PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL DENTAL PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL DENTAL PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL MUSCULOSKELETAL INJURY (SPRAIN/STRAIN) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL MUSCULOSKELETAL INJURY (SPRAIN/STRAIN) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL MUSCULOSKELETAL INJURY (SPRAIN/STRAIN) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL POSTOPERATIVE PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL POSTOPERATIVE PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL POSTOPERATIVE PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL DYSMENORRHEA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL DYSMENORRHEA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL DYSMENORRHEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL FEVER/PYREXIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL FEVER/PYREXIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL FEVER/PYREXIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL MIGRAINE & HEADACHE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL MIGRAINE & HEADACHE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL MIGRAINE & HEADACHE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL OPHTHALMIC PAIN & INFLAMMATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL OPHTHALMIC PAIN & INFLAMMATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL OPHTHALMIC PAIN & INFLAMMATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 236. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 266. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 268. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 272. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 274. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 276. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
  • TABLE 278. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 280. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 295. AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
  • TABLE 297. AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 298. AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 299. AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 300. AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 302. AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 304. MIDDLE EAST NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 306. MIDDLE EAST NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
  • TABLE 308. MIDDLE EAST NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 310. MIDDLE EAST NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 312. MIDDLE EAST NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 314. MIDDLE EAST NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
  • TABLE 316. MIDDLE EAST NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 318. MIDDLE EAST NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 320. MIDDLE EAST NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 322. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 323. NATO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 324. NATO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 325. NATO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 326. NATO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
  • TABLE 327. NATO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
  • TABLE 328. NATO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 329. NATO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 330. NATO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
  • TABLE 331. NATO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 332. NATO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 333. NATO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 334. NATO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 335. NATO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
  • TABLE 336. NATO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 337. NATO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 338. NATO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 339. NATO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 340. NATO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 341. NATO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 342. G7 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 343. G7 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 344. G7 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC